The race for oral obesity drugs is heating up as pharma giants Novo Nordisk and Eli Lilly prepare to bring GLP-1 pills to markets including India. Mayuresh Joshi, Head Equity Research, William O’Neil India, explains the growing opportunity in oral anti-obesity medicines and highlights companies that could benefit from the expansion of the GLP-1 market. The discussion also covers Dr Reddy’s, Cipla and ancillary players, along with the potential for the global GLP-1 market to grow sharply over the next four to five years. Business Today’s Neetu Chandra Sharma brings the latest updates on the expected India launch timeline and regulatory approvals.
Goldman Sachs pushes back on 'short-AI' India narrative, says report; 42 stocks in focus
Indian pilot Smit Machchhar airlifted to Abu Dhabi for advanced medical care
U.S. Leaves Iraq After 23 Years: Who Will Fill The Power Vacuum? 
IOC Buys Iraqi Crude At $32 Discount: What It Means For Refining Margins & Profitability
Global bond yields hit multi-decade highs as oil, inflation and debt worries mount: ReportGoldman Sachs pushes back on 'short-AI' India narrative, says report; 42 stocks in focus
PB Fintech shares crash 48% in six sessions; stock barely holds above IPO price
Welspun Living shares gain 5%; Jefferies retains 'Buy' call; check target price
Nifty extends slide to eighth straight week, longest in 25 years; TMPV, Maruti, M&M, Jio Financial among top drags
Rs 2.7 lakh crore gone! Tata Sons tussle wipes out 10% value of Tata group stocksU.S. Leaves Iraq After 23 Years: Who Will Fill The Power Vacuum? IOC Buys Iraqi Crude At $32 Discount: What It Means For Refining Margins & Profitability
New-Age Stocks: Why Quick Commerce Could Be The Next Big Consumption Opportunity
CDMO Stocks: Why The Sector Could See Strong Long-Term Growth
Drishyam, Prem Keetanu, Doraemon: Your Guide To This Weekend’s New Theatre Releases 
